Specialised for every product type entering Europe and the US.
A small molecule, a cell therapy and a device need different evidence and pathways in Europe and the US. We assess the product, its intended use and the expertise required for the engagement.
Innovative, generic and biosimilar medicines
Clinical trial and marketing authorisation strategy, EU GMP readiness and lifecycle planning for medicines, including drug-led combination products.
- Centralised, DCP / MRP and national MAAs
- EU GMP and FDA inspection readiness
- Biosimilar comparability strategy
Biologics, ATMPs and novel modalities
Scientific advice, orphan designation, PRIME eligibility and clinical evidence planning for biologics and advanced therapies.
- Scientific advice & PRIME / orphan strategy
- ATMP GMP & supply-chain considerations
- First-in-human to pivotal, Europe and the US
MDR and IVDR conformity, done properly
Classification, conformity route, technical documentation and device clinical evaluation or IVD performance evaluation, with product-specific post-market requirements.
- Notified-body selection & conformity route
- Clinical / performance evidence and technical file requirements
- Representative, US Agent and registration requirements
Combination products, diagnostics and digital health.
Many of the most interesting products don't fit neatly into one regulatory box. Drug-led combinations, companion diagnostics and software as a medical device require a product-specific assessment of medicinal-product and device requirements.
Kaiveo Medical scopes these cases individually, bringing the right mix of regulatory, clinical and quality expertise to a single plan.
Discuss a hybrid productDrug–device combinations
Article 117 assessment for integral products where applicable; CE requirements for co-packaged devices.
Companion diagnostics
IVDR performance evaluation aligned with the medicinal-product development plan.
Software & AI as a medical device
MDR classification, clinical evaluation and cybersecurity expectations for SaMD.
Emerging modalities
Novel platforms where the regulatory route is still being defined.
Tell us what you're bringing to market.
A founder will review your product needs and the expertise required before an engagement is agreed.
We aim to reply within two working days. Language support is agreed for each engagement.
